Two drug combination shows protection against severe COVID-19

Two drug combos show protection against severe COVID-19 CIDRAP

Two new randomized, controlled trials published yesterday in the Annals of Internal Medicine describe how drug combinations lowered the risk of severe COVID-19, with one detailing use of the antidepressant fluvoxamine plus the corticosteroid budesonide, and the other outlining the monoclonal antibody duo amubarvimab plus romlusevimab.

Fluvoxamine plus budesonide effective, safe

In the TOGETHER adaptive platform trial of repurposed drugs, a Stanford University–led team evaluated the use of the oral selective serotonin reuptake inhibitor fluvoxamine plus the inhaled corticosteroid budesonide among nonhospitalized adults with early symptomatic COVID-19 and at least one risk factor for severe disease at 12 sites in Brazil from January 15 to July 6, 2022.

...